GHRH Analogue · DAC Modified Research Compound WADA Prohibited

CJC-1295

DAC:GRF · Drug Affinity Complex GRF · Long-Acting GHRH

"A single injection that sustains elevated growth hormone for nearly a week. The convenience-first GHRH analogue — one or two injections weekly instead of three daily. The tradeoff: less physiological, harder to control if problems arise."

Structure
GHRH analogue · albumin-binding DAC
FDA Status
Not approved · Research compound
Half-life
6–8 days (vs 30 min for Mod-GRF)
Phase II trial
2–10x GH elevation · sustained 6 days
WADA
Prohibited
Origin & Background

The long-acting GHRH analogue

CJC-1295 with DAC is a GHRH analogue with a Drug Affinity Complex (DAC) — a chemical modification that enables the peptide to covalently bind to albumin in the bloodstream. Albumin is the most abundant plasma protein and has a half-life of approximately 19 days. By hitching a ride on albumin, CJC-1295 is slowly released over 6–8 days from a single injection, producing sustained GH stimulation far longer than any other GHRH analogue.

It was studied in a pivotal 2006 Phase II clinical trial (Teichman et al., Journal of Clinical Endocrinology & Metabolism) that remains the most cited evidence for any GHRH analogue. The trial in healthy adults showed dose-dependent GH increases of 2–10 fold lasting 6 days, and IGF-1 elevations lasting 9–11 days. After multiple doses, IGF-1 remained elevated for up to 28 days. No serious adverse events were reported at doses of 30–60 mcg/kg.

Despite this clinical data, CJC-1295 with DAC was not developed further as a pharmaceutical — likely due to the concerns about sustained non-pulsatile GH elevation and the commercial landscape. It became a research compound widely used in functional medicine, anti-ageing clinics, and the biohacking community, typically combined with ipamorelin.

DAC vs no-DAC — the fundamental difference: CJC-1295 with DAC and Mod-GRF 1-29 (CJC-1295 without DAC) are completely different in pharmacokinetics despite sharing the same base peptide. DAC = weekly dosing, sustained continuous GH elevation, less physiological. No-DAC = daily/multiple daily dosing, pulsatile GH, more physiological. Knowing which version you have is essential — they are not interchangeable.

Science & Mechanism

Albumin binding extends everything

Mechanism of Action

1
GHRHR binding: The base GHRH peptide binds to GHRH receptors on pituitary somatotrophs, activating adenylate cyclase and stimulating GH synthesis and release — identical mechanism to sermorelin and Mod-GRF.
2
Albumin covalent binding (DAC): The DAC modification creates a maleimide reactive group that covalently binds to cysteine-34 on albumin after injection. This creates a large albumin-peptide complex that resists renal filtration and proteolytic degradation, extending half-life to 6–8 days.
3
Sustained GH elevation: Rather than a discrete pulse, CJC-1295 DAC produces continuous, low-grade GH stimulation throughout the week. GH levels remain above baseline for the full dosing interval — unlike natural GH which pulses every few hours and falls to baseline between pulses.
4
Synergy with ipamorelin: Even on a background of continuous CJC-1295 GH elevation, adding ipamorelin creates additional sharp GH spikes through the independent ghrelin receptor. The 3–5x synergistic amplification documented for Mod-GRF also applies when ipamorelin is added to the CJC-1295 DAC baseline.
5
IGF-1 cumulative elevation: With weekly dosing, IGF-1 accumulates above baseline throughout the dosing period and can remain elevated for up to 28 days with repeated dosing. This produces the body composition effects of chronically elevated GH/IGF-1 — more consistent but less physiological than pulsatile alternatives.

The Phase II trial (Teichman 2006, n=64 healthy adults) is the best clinical evidence for any GHRH analogue outside of tesamorelin. At 30 and 60 mcg/kg doses, mean GH was elevated 2–10 fold for 6 days post-injection. IGF-1 rose 1.5–3 fold and remained elevated 9–11 days. After multiple doses, mean IGF-1 stayed above baseline for 28 days. This evidence is what separates CJC-1295 DAC from many research peptides — it has human pharmacokinetic and pharmacodynamic data from a proper clinical trial.

DAC vs No-DAC Comparison

Choosing between the two versions

CJC-1295 with DAC
Half-life6–8 days
Dosing1–2x weekly
GH patternContinuous baseline elevation
Side effect controlSlow to resolve (days)
Physiological?Less — non-pulsatile
Best forConvenience, adherence
Clinical dataPhase II RCT (2006)
Mod-GRF 1-29 (no DAC)
Half-life~30 minutes
Dosing2–3x daily
GH patternDiscrete pulses
Side effect controlRapid — hours to clear
Physiological?More — mimics natural rhythm
Best forControl, precision
Clinical dataMechanistic only

The practical verdict: If you will reliably inject 2–3 times daily and want maximum physiological accuracy, Mod-GRF 1-29 is the better choice. If adherence to frequent dosing is a challenge, CJC-1295 with DAC produces comparable GH/IGF-1 elevation with once or twice weekly injections — at the cost of less control and less pulsatile physiology. Most clinic protocols now favour Mod-GRF + ipamorelin for its controllability, but CJC DAC remains widely used for convenience.

Community Voices

What people report

Anecdotal ReportNot medical evidence · Individual experience

"The convenience is real — one injection Monday, another Thursday, done. My IGF-1 went from 130 to 195 within 8 weeks. The water retention was the main issue at the higher dose. Dropped to 1mg weekly and it was manageable."

Male, 48, using CJC-1295 DAC 1–2mg weekly with ipamorelin 100mcg nightly. Water retention is the most consistently reported dose-dependent side effect — driven by sustained IGF-1 elevation and sodium retention. Dose reduction reliably resolves it, but unlike Mod-GRF, takes days rather than hours to clear.

Anecdotal ReportNot medical evidence · Individual experience

"Started on CJC DAC because I travel and couldn't manage multiple daily injections. Switched to Mod-GRF + ipa after 6 months. The pulsatile version feels cleaner — less bloat, more energy variability that matches training. But the DAC version absolutely worked."

Female, 39, experienced peptide user. This progression — starting on CJC DAC for convenience, switching to Mod-GRF for control — is common among users who become more experienced with GH protocols.

Benefits & Evidence

What the data shows

📈
GH and IGF-1 elevation — best clinical evidence
Teichman Phase II (2006): 2–10x GH elevation lasting 6 days per injection; IGF-1 elevation 1.5–3x lasting 9–11 days; cumulative IGF-1 above baseline for 28 days with repeated dosing. The most robust human pharmacokinetic evidence of any GHRH analogue outside tesamorelin.
● Strong — Phase II RCT in healthy adults
💪
Body composition (via sustained GH/IGF-1)
Chronic GH/IGF-1 elevation drives protein synthesis, lipolysis, and lean mass accrual. Body composition changes emerge over 3–6 months of consistent use and are among the most reported benefits in both community and clinical contexts.
● Moderate — extrapolated from GH axis literature
🔁
Recovery and sleep quality
Sustained GH/IGF-1 elevation supports tissue repair and deep sleep quality. Users consistently report faster recovery between training sessions and improved sleep depth — effects that emerge within the first few weeks of use.
● Moderate — consistent community reports
🗓️
Dosing convenience
Once or twice weekly injection versus 2–3 times daily for Mod-GRF. For people who travel, work irregular hours, or struggle with frequent injection adherence, this is a meaningful practical advantage that directly affects real-world outcomes.
● Practical advantage — not a clinical evidence category
Safety First

Risks & considerations

⚠️
The primary safety concern unique to the DAC version is the slow clearance. With Mod-GRF, stopping an injection means the peptide is gone in 30 minutes. With CJC-1295 DAC, if you develop water retention, joint pain, or elevated IGF-1, you cannot rapidly stop the effect — you are committed to 6–8 days of exposure per injection. This fundamentally changes the risk-management calculus.
Moderate
Water retention and oedema — the most common side effect. Sustained IGF-1 causes sodium retention. More pronounced and more persistent than with Mod-GRF due to the longer half-life. Dose reduction is the fix — but takes days to work.
Moderate
Joint discomfort and carpal tunnel symptoms — another IGF-1 mediated effect. Dose-dependent. More common at higher weekly doses (2mg+). Resolves with dose reduction but slowly.
Moderate
Elevated IGF-1 — chronic sustained IGF-1 elevation is the theoretical long-term risk. Monitor every 3 months. Keep within age-appropriate reference ranges. The sustained elevation profile of CJC DAC may produce higher average IGF-1 than pulsatile alternatives.
Moderate
Potential receptor desensitisation — continuous GHRH receptor stimulation may lead to downregulation over time. This is the theoretical basis for cycling (12–16 weeks on, 4–8 weeks off) and is one reason practitioners increasingly prefer the pulsatile Mod-GRF approach.
Serious
Contraindicated in active malignancy — as with all GH-axis compounds. The sustained IGF-1 elevation from CJC DAC makes this contraindication particularly important.

⚠ Key Warnings

Start at 1mg weekly, not 2mg. The sustained half-life means you live with side effects for a week if you overdose. Conservative starting doses allow calibration before committing to higher doses.
Monitor IGF-1, fasting glucose and HbA1c every 3 months. More critical with the DAC version due to sustained elevation.
WADA prohibited at all times for competitive athletes.
Always inject fasted — insulin suppresses GH release even with the long-acting version.
Do not confuse with Mod-GRF 1-29 (CJC-1295 without DAC) — they have completely different half-lives and dosing protocols.
Synergy Stack

Nutrients, Supplements & Exercise

CJC-1295 DAC's synergies are identical to Mod-GRF 1-29 — the downstream GH/IGF-1 effects are the same, just sustained differently. The key practical differences are in timing and side effect management.

💊 Nutrients & Supplements
Ipamorelin
100–200mcg SubQ nightly
Strong evidence
The standard combination. Even on the sustained CJC DAC baseline, adding ipamorelin nightly amplifies the nocturnal GH pulse through the independent ghrelin receptor. This is the most widely used clinic protocol worldwide — CJC DAC weekly plus ipamorelin nightly.
Protein (1.8–2.4g/kg/day)
Essential substrate
Strong evidence
Chronically elevated IGF-1 from CJC DAC drives mTOR-dependent protein synthesis. Without adequate protein, the anabolic signal has no raw material. The sustained elevation makes consistent protein intake more important than with pulsatile protocols.
No carbs at injection time
Fasted state for weekly injection
Strong evidence
Even with a 6–8 day half-life, the initial GH pulse at injection is blunted by insulin. Inject CJC DAC fasted for the highest initial GH response — typically before bed on injection day.
Dandelion root (for water retention)
500mg/day if oedema occurs
Limited evidence
Natural diuretic used by experienced peptide users to manage CJC DAC-induced water retention. Limited clinical evidence but widely used as a harm reduction strategy. If retention is significant, dose reduction is more effective and more appropriate.
🏃 Exercise & Lifestyle
Resistance training throughout the cycle
Sustained GH/IGF-1 elevation from CJC DAC requires consistent resistance training to direct the anabolic signal toward muscle. Without training stimulus, elevated GH/IGF-1 produces less body composition benefit.
Consistent injection day
Weekly CJC DAC injections should be on the same day each week to maintain consistent plasma levels. Irregular timing creates troughs and peaks in IGF-1 that are less predictable than a consistent schedule.
Monitor for water retention weekly
With a 6–8 day half-life, side effects accumulate week-on-week. Weekly weigh-in and observation for ankle/finger swelling identifies retention early — before it becomes uncomfortable or problematic.
⏱ Timing & Protocol Notes
Standard: 1–2mg CJC-1295 DAC SubQ once weekly, fasted (before bed on injection day). Combine with 100–200mcg ipamorelin nightly SubQ, also fasted. Cycle 12–16 weeks, then 4–8 weeks off. Monitor IGF-1 at weeks 6 and 12. Start at 1mg weekly — do not start at 2mg. The 6–8 day half-life means you are committed to a full week of exposure per injection.

Disclaimer: CJC-1295 with DAC is a research compound with no FDA approval. Physician oversight and regular monitoring are required. The sustained half-life makes careful starting dose selection particularly important — there is no rapid off-switch.

Honest Assessment

Editor's summary

CJC-1295 with DAC has the best clinical evidence of any non-approved GHRH analogue — the 2006 Phase II trial provides real human pharmacokinetic and pharmacodynamic data that most research peptides simply don't have. The GH and IGF-1 elevations are documented, substantial, and reproducible.

The honest trade-off is physiological vs convenient. Natural GH is pulsatile for good reasons — the body regulates each pulse through somatostatin feedback, creating natural troughs that prevent chronic overstimulation. CJC DAC bypasses this rhythm. Whether continuous elevation matters clinically over the typical 12–16 week cycle is unknown, but it is the mechanistic basis for the community preference for Mod-GRF + ipamorelin in many clinic protocols.

For most people starting GH peptide protocols, Mod-GRF + ipamorelin is the more physiological and controllable choice. CJC DAC makes sense for people who know they will struggle with multiple daily injections and want a proven convenience-first approach with real clinical data behind it.

Verdict
"The most evidence-backed non-approved GHRH analogue. Convenient weekly dosing, real Phase II data, meaningful GH/IGF-1 elevation. Less physiological than pulsatile alternatives and side effects take days to resolve rather than hours. An excellent starting point — but understand the commitment each injection represents."